Acadia Pharmaceuticals stock drops after ACP-101 misses endpoint

Acadia Pharmaceuticals (ACAD) shares declined 11% after its ACP-101 drug candidate failed to meet its primary endpoint in clinical trials, leading to its discontinuation and underperforming the broader biotech sector. Despite this setback, analysts like Leerink Partners maintained positive ratings, citing Acadia's robust financial position and the market's prior discounting of the failed program, while expressing optimism for the company's next pipeline candidate, ACP-204. The development also benefited competitor Soleno Therapeutics, whose stock surged as Acadia's exit removed a significant competitive overhang in the Prader-Willi syndrome treatment market.

Analysis

Acadia Pharmaceuticals (ACAD) experienced an 11% stock decline after its ACP-101 drug candidate for Prader-Willi syndrome (PWS) failed to meet its primary clinical trial endpoint, leading to the program's discontinuation. This drop of approximately $2.50 per share exceeded some analyst expectations and caused the stock to underperform the biotech sector, as the XBI index rose 1% on the same day. Despite the setback, several research firms, including Leerink Partners and Baird, maintained 'Outperform' ratings with price targets of $32 and $31, respectively. The rationale for this continued confidence is rooted in Acadia's robust financial health—highlighted by a current ratio of 2.91, LTM revenue growth of 14.4%, more cash than debt, and positive earnings—and the view that the market had already assigned minimal value to the now-defunct pipeline asset. The investment thesis now shifts to the company's strong base business performance and its next major pipeline candidate, ACP-204, for which data is expected in mid-2026. The failure of ACP-101 has also reshaped the competitive landscape, creating a significant tailwind for competitor Soleno Therapeutics (SLNO), which saw its stock rise as a key competitive threat was eliminated.

Key Decisions for Investors

• Investors should evaluate the 11% share price decline as a potential entry point, as the market reaction appears to be focused on a pipeline asset that analysts had already largely discounted, while the company's strong fundamentals and core business remain intact.
• The primary forward-looking catalyst is now the development of ACP-204 for Alzheimer's disease psychosis; however, with data not expected until mid-2026, the investment thesis in the near-to-medium term will depend on the performance of Acadia's base business.
• For investors focused on the PWS treatment space, Acadia's exit creates a clearer path for competitor Soleno Therapeutics (SLNO), suggesting a potential re-evaluation of positions or a relative value trade between the two entities.